Innate Immunotherapeutics is looking to raise up to AUD12m ($11m) before costs through the public offer of up to 60m shares at AUD0.20 each to progress the development of a novel therapy for serious multiple sclerosis.
written on 29.11.2013
UPDATE: Innate seeks $11m in IPO to support lead MS candidate
